The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3).

Abstract

OBJECTIVE:

To determine the effect of vitamin D3 analogue (EB-1089) on the growth and proliferation of a prostate cancer cell line (PC-3).

MATERIALS AND METHODS:

PC-3 cells (10(4) cells per well) were plated into 24-well tissue culture plates. After 24 h, the culture medium was replaced with one containing the vitamin D3 analogue EB-1089; a control treatment using only replacement medium was conducted in parallel. Cell proliferation was measured by the incorporation of 3H-thymidine 7 and 12 days after the addition of the vitamin D3 analogue. Cells were precipitated with 5% trichloroacetic acid and the radioactivity determined using a scintillation counter. Each experiment was performed at least five times.

RESULTS:

There was a significant dose-dependent inhibition of cell growth after 7 and 12 days of treatment with EB-1089, varying from 40 to 70% of the 3H-thymidine incorporation by controls, respectively. The maximum inhibition occurred with 0.1 micromol/L EB-1089 on day 7 and day 12 (both P < 0.01). Longer incubation times appeared to have a greater effect when higher concentrations of EB-1089 were used.

CONCLUSION:

These in vitro studies have shown that the vitamin D3 analogue EB-1089 can significantly reduce the growth rate of the prostate cancer cell line PC-3. This would support the hypothesis that deficiency of vitamin D increases the risk of prostate cancer and further in vivo testing of vitamin D is warranted for its potential role in active therapy.

• Authors: X Wang, X Chen, J Akhter, D L Morris
• Journal: British journal of urology (Br J Urol) Vol. 80 Issue 2 Pg. 260-2 (Aug 1997) ISSN: 0007-1331 [Print] England
• PMID: 9284199 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Calcitriol
• seocalcitol

Topics

• Antineoplastic Agents (therapeutic use)
• Calcitriol (analogs & derivatives, therapeutic use)
• Cell Division (drug effects)
• Dose-Response Relationship, Drug
• Humans
• Male
• Prostatic Neoplasms (drug therapy, pathology)
• Risk Factors
• Tumor Cells, Cultured (pathology)